Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Leukemia. 2019 Aug 19;34(1):210–223. doi: 10.1038/s41375-019-0540-7

Figure 3. Increased immune responses of BCMA-specific CTL induced with BCMA peptide-encapsulated nanoparticles against multiple myeloma cell lines.

Figure 3.

Figure 3.

Figure 3.

HLA-A2-restrcited anti-myeloma activities of heteroclitic BCMA-specific CTL generated from HLA-A2+ normal donor’s PBMC by stimulation with (1) free peptide, (2) PLGA/peptide or (3) liposome/peptide. Functional immune activities were assessed by (A) CD107a degranulation, (B) IFN-γ production, (C) IL-2 production, and (D) TNF-α production.